Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Novartis AG Common Stock (NY: NVS ) 98.35 -0.10 (-0.10%) Official Closing Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 337,383 Open 98.21 Bid (Size) 95.05 (2) Ask (Size) 99.72 (2) Prev. Close 98.45 Today's Range 97.67 - 98.45 52wk Range 92.35 - 120.92 Shares Outstanding N/A Dividend Yield 3.84% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services December 19, 2024 U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. Via Benzinga For those who appreciate value investing, NYSE:NVS is a compelling option with its solid fundamentals. December 19, 2024 NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. Via Chartmill Performance YTD -2.62% -2.62% 1 Month -5.01% -5.01% 3 Month -15.52% -15.52% 6 Month -8.40% -8.40% 1 Year -0.20% -0.20% More News Read More Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers December 18, 2024 Via FinancialNewsMedia Why the dividend investor may take a look at NYSE:NVS. December 13, 2024 Via Chartmill 2 Dividend Stocks to Buy and Hold Forever December 01, 2024 Via The Motley Fool Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers December 18, 2024 From FN Media Group LLC Via GlobeNewswire Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report December 13, 2024 Via Benzinga Exploring NYSE:NVS's dividend characteristics. November 22, 2024 Via Chartmill Is NYSE:NVS suited for dividend investing? November 01, 2024 Via Chartmill Novartis Reports Q3 Momentum, But Shares Lose Support October 29, 2024 Via Investor's Business Daily UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug December 10, 2024 Via Investor's Business Daily Exposures Product Safety Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder December 06, 2024 Via Benzinga Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst December 03, 2024 Via Benzinga PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program December 02, 2024 Via Benzinga PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone December 02, 2024 Via Investor's Business Daily Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline November 21, 2024 Via Benzinga Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details November 12, 2024 Via Benzinga Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review November 01, 2024 Via Investor's Business Daily Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights October 30, 2024 Via Benzinga Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy October 30, 2024 Via Benzinga Novartis Ag (NVS) Q3 2024 Earnings Call Transcript October 29, 2024 Via The Motley Fool Topics Earnings Exposures Financial Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook October 29, 2024 Via Benzinga Topics Earnings Exposures Financial Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis October 28, 2024 Via Investor's Business Daily “Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” October 28, 2024 Via AB Newswire Topics Artificial Intelligence Exposures Artificial Intelligence Why Is Monte Rosa Therapeutics Stock Surging On Monday? October 28, 2024 Via Benzinga Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
